Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLCP-008-1
- Development stage
- Preclinical
- Lead developer
- Galenica
- Modality
- Small Molecules
01
Overview
GLCP-008-1 is a small molecule therapeutic candidate being developed by Galenicap for the treatment of relapsed or refractory acute myeloid leukemia (AML). The drug is part of Galenicap's oncology portfolio, which focuses on identifying and developing targeted therapies for cancers with high unmet medical needs. While the specific mechanism of action and molecular target for GLCP-008-1 have not been publicly detailed in the company's pipeline documentation, the program is positioned to address patients who have failed standard treatments for AML. The asset is currently in the early stages of development, following the company's strategy of disrupting key oncogenic drivers in hematological malignancies.
Beyond the preview
Go deeper on GLCP-008-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLCP-008-1.